MCT9 CRISPR Activation Plasmid (h): sc-409073-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- MCT9 CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- MCT9 CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by MCT9 CRISPR Activation Plasmid (h) and MCT9 CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the SLC16A9 transcriptional start site. One or both designs may be available
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
MCT9 CRISPR Activation Plasmid (h) | sc-409073-ACT | 20 µg | $397.00 | |||
MCT9 CRISPR Activation Plasmid (h2) | sc-409073-ACT-2 | 20 µg | $397.00 |
SLC16A9 encodes monocarboxylate transporter 9 (MCT9), a membrane carrier in the solute carrier 16 family implicated in transmembrane movement of small organic acids and related metabolites. MCT9 contributes to cellular metabolic homeostasis by influencing substrate availability for mitochondrial oxidation, redox balance, and broader nutrient-sensing processes. Expression patterns and genetic associations link SLC16A9 to systemic metabolite regulation, including urate handling and kidney-associated transport physiology. As a result, SLC16A9 is frequently studied in the context of metabolic traits and disorders where altered metabolite flux and transporter activity shape cell and tissue function.
MCT9 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous SLC16A9 expression without altering the underlying DNA sequence.
MCT9 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the SLC16A9 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the SLC16A9 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous MCT9 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native SLC16A9 locus and enabling the study of MCT9-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of MCT9 pathway restoration in tumor cells with silenced or reduced SLC16A9 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.